Kiniksa Pharmaceuticals International, plc KNSA Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's contract liabilities?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported contract liabilities of $31.81M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's contract liabilities changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's contract liabilities decreased by 0.0% year-over-year, from $31.81M to $31.81M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's contract liabilities?
- Over 3 years (2022 to 2025), Kiniksa Pharmaceuticals International, plc's contract liabilities has grown at a 38.4% compound annual growth rate (CAGR), from $12M to $31.81M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.